Flach, Johanna; Shumilov, Evgenii; Wiedemann, Gertrud; Porret, Naomi; Shakhanova, Inna; Bürki, Susanne; Legros, Myriam; Joncourt, Raphael; Pabst, Thomas; Bacher, Ulrike (2020). Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. Hematological oncology, 38(4), pp. 425-431. Wiley 10.1002/hon.2739
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Clinical potential.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (576kB) |
Relapse of acute myeloid leukemia (AML) remains a major determinant of outcome. A number of molecularly directed treatment options have recently emerged making comprehensive diagnostics an important pillar of clinical decision making at relapse. Acknowledging the high degree of individual genetic variability at AML relapse, next-generation sequencing (NGS) has opened the opportunity for assessing the unique clonal hierarchy of individual AML patients. Knowledge on the genetic makeup of AML is reflected in patient customized treatment strategies thereby providing improved outcomes. For example, the emergence of druggable mutations at relapse enable the use of novel targeted therapies, including FLT3 inhibitors or the recently approved IDH1/2 inhibitors ivosidenib and enasidenib, respectively. Consequently, some patients may undergo novel bridging approaches for reinduction before allogeneic stem cell transplantation, or the identification of an adverse prognostic marker may initiate early donor search. In this review, we summarize the current knowledge of NGS in identifying clonal stability, clonal evolution, and clonal devolution in the context of AML relapse. In light of recent improvements in AML treatment options, NGS-based molecular diagnostics emerges as the basis for molecularly directed treatment decisions in patients at relapse.
Actions (login required)
 |
Edit item |